Trial Profile
A Phase 3b, Multicenter, Open-label, Randomized Withdrawal Trial of the Effects of Titrated Oral SAMSCA (Tolvaptan) on Serum Sodium, Pharmacokinetics, and Safety in Children and Adolescent Subjects Hospitalized With Euvolemic or Hypervolemic Hyponatremia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hyponatraemia
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 25 Oct 2017 Status changed from recruiting to discontinued.
- 29 Aug 2017 This trial has been Discontinued in Spain (end date: 24 Jul 2017).
- 05 Aug 2017 This trial has been completed in Belgium (end date: 24 Jul 2017).